Guadalupe Echeverría1, Catalina Dussaillant2, Luis Villarroel3, Attilio Rigotti4. 1. Centre for Molecular Nutrition and Chronic Diseases, Pontificia Universidad Católica de Chile, Santiago, Chile. 2. Centre for Molecular Nutrition and Chronic Diseases, Pontificia Universidad Católica de Chile, Santiago, Chile; Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 3. Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 4. Centre for Molecular Nutrition and Chronic Diseases, Pontificia Universidad Católica de Chile, Santiago, Chile; Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address: arigotti@med.puc.cl.
Abstract
BACKGROUND: In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) jointly released new guidelines for cardiovascular risk assessment and cholesterol management that substantially modified the previous recommendations proposed by the National Cholesterol Education Program (NCEP) in 2001. The relative impact of these new guidelines on potential statin use has not been estimated in Latin American populations. OBJECTIVE: To estimate and compare eligibility for statin therapy based on ACC/AHA and NCEP guidelines in adult Chilean population. METHODS: Using data from the last National Health Survey (2009-2010 NHS), we conducted a cross-sectional analysis in a representative sample of the Chilean adult population and calculated the proportion of individuals that would receive statins under each set of guidelines. RESULTS: According to ACC/AHA guidelines, the population eligible for statin treatment increased from 21.7% (NCEP guidelines) to 33.2% (overall 53% increase). This effect was more pronounced among women (29.6% under ACC/AHA vs 15.6% under NCEP) and with those of advanced age (75% of the subjects >60 years of age compared with 46% under NCEP). The newly eligible group included more women and older subjects and individuals with lower LDL cholesterol levels. CONCLUSION: Compared with NCEP recommendations, the new ACC/AHA guidelines significantly increased the number of Chilean adults eligible for statin therapy. Full implementation of the new recommendations may have important public health implications in Chile and other Latin American countries, as more women and older subjects without cardiovascular disease would qualify for statin treatment.
BACKGROUND: In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) jointly released new guidelines for cardiovascular risk assessment and cholesterol management that substantially modified the previous recommendations proposed by the National Cholesterol Education Program (NCEP) in 2001. The relative impact of these new guidelines on potential statin use has not been estimated in Latin American populations. OBJECTIVE: To estimate and compare eligibility for statin therapy based on ACC/AHA and NCEP guidelines in adult Chilean population. METHODS: Using data from the last National Health Survey (2009-2010 NHS), we conducted a cross-sectional analysis in a representative sample of the Chilean adult population and calculated the proportion of individuals that would receive statins under each set of guidelines. RESULTS: According to ACC/AHA guidelines, the population eligible for statin treatment increased from 21.7% (NCEP guidelines) to 33.2% (overall 53% increase). This effect was more pronounced among women (29.6% under ACC/AHA vs 15.6% under NCEP) and with those of advanced age (75% of the subjects >60 years of age compared with 46% under NCEP). The newly eligible group included more women and older subjects and individuals with lower LDL cholesterol levels. CONCLUSION: Compared with NCEP recommendations, the new ACC/AHA guidelines significantly increased the number of Chilean adults eligible for statin therapy. Full implementation of the new recommendations may have important public health implications in Chile and other Latin American countries, as more women and older subjects without cardiovascular disease would qualify for statin treatment.
Authors: Waqas T Qureshi; Robert C Kaplan; Katrina Swett; Gregory Burke; Martha Daviglus; Molly Jung; Gregory A Talavera; Diana A Chirinos; Samantha A Reina; Sonia Davis; Carlos J Rodriguez Journal: J Am Heart Assoc Date: 2017-05-11 Impact factor: 5.501